Unique ID issued by UMIN | UMIN000008318 |
---|---|
Receipt number | R000006107 |
Scientific Title | Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study |
Date of disclosure of the study information | 2012/07/02 |
Last modified on | 2012/07/02 13:13:55 |
Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study
Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study
Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study
Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study
Japan |
lung cancer
Pneumology |
Malignancy
NO
To examine the effect of additional apreptant to palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer.
Safety,Efficacy
Phase II
Complete Response (CR) rate
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Palonosetoron+Dexamethasone
Palonosetoron+Aprepitant+Dexamethasone
20 | years-old | <= |
80 | years-old | > |
Male and Female
1)No prior chemotherapy
2)Patient receiving combination chemotherapy with CBDCA and moderately emetogenic anticancer drugs
7)Written IC.
1)vomiting within 24h before first chemotherapy
2)continuatory use of severely or moderately emetogenic anticancer drugs after Day 2
3)concurrent radiotherapy
4) Severe complications
5)Symptomatic brain meta
6)Hypersensitivity for PaIonosetron, Aprepitant, Dexamethasone
7) Other patients who are unfit for the study as determined by the attending physician.
50
1st name | |
Middle name | |
Last name | Yoshiki Ishii |
Dokkyo Medical University
Department of Pulmonary Medicine and Clinical Immunology
880 Kitakobayashi, Mibu, Tochigi, Japan
1st name | |
Middle name | |
Last name | Yoshiki Ishii |
Dokkyo Medical University
Department of Pulmonary Medicine and Clinical Immunology
ishiiysk@dokkyomed.ac.jp
Dokkyo Medical University
Dokkyo Medical University
Self funding
NO
2012 | Year | 07 | Month | 02 | Day |
Unpublished
Open public recruiting
2011 | Year | 02 | Month | 10 | Day |
2012 | Year | 07 | Month | 01 | Day |
2012 | Year | 07 | Month | 02 | Day |
2012 | Year | 07 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006107